Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

In an era where pharmaceutical companies are constantly innovating, Pfizer Inc. stands at a crossroads. The drugmaker recently announced that it anticipates little to no sales growth for the upcoming ...

As 2026 begins, Pfizer is deploying a dual strategy of pharmaceutical price increases and targeted investor outreach. The market is watching closely to see if this year will mark the promised ...

US pharma major Pfizer (NYSE: PFE) has struck a non-exclusive research collaboration with Gordian Bio to identify new ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...